FDA signs off on CF102 Phase 2 protocol

The U.S. Regulator agrees with Can-Fite BioPharma's (CANF) Phase 2 protocol for the Orphan Drug-designated CF102 for the treatment of advanced liver cancer. The 78-patient trial will evaluate the safety and efficacy of CF102 as a second-line treatment for advanced hepatocellular carcinoma (HCC) with Child-Pugh Class B cirrhosis in patients who have failed sorafenib.

In a completed Phase 1/2 trial, CF102 demonstrated an excellent safety profile, lack of hepatotoxicity, prolonged survival time compared to placebo, regression of skin tumor metastases and a stabilization of the disease in 22% of patients.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs